Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from JHVEPhoto

Why Carter's Biggest Challenge Yet Could Hit Your Kids' Closet Next

Carter’s Inc. (NYSE:CRI) on Monday reported mixed third-quarter results before the market open, with earnings coming in slightly above Wall Street estimates while revenue was marginally below expectations.

BNY Mellon Ready To Accelerate As Profit Margins Climb

BNY Mellon Ready To Accelerate As Profit Margins Climb

In a rapidly evolving financial landscape, banks are seeking new avenues to boost profitability and enhance growth prospects. Bank of New York Mellon Corp (NYSE:BK) has room for margin expansion and to accelerate its growth rate, according to Keefe, Bruyette Woods.

State Street Profit Rises As CEO Touts Record Management Fees

State Street Profit Rises As CEO Touts Record Management Fees

State Street Corporation (NYSE:STT) stock fell on Friday after reporting third-quarter results.

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

BNY Hits Record Revenue As CEO Says Growth Strategy Is Paying Off

The Bank of New York Mellon Corporation or BNY (NYSE:BK) reported third-quarter 2025 diluted EPS of $1.88 and adjusted diluted EPS of $1.91, beating the $1.77 estimate.

EMA Backs Amgen Drug For Rare Autoimmune Disorder

The European Medicines Agency’s (EMA) human medicines committee (CHMP) has recommended extending the therapeutic indication of Amgen Inc.’s (NASDAQ:AMGN) Uplizna (inebilizumab) to include the treatment of adult patients with active immunoglobulin G4-related disease (IgG4-RD).

Wolverine Expands Jordan Davis Partnership With Bold Lifestyle Collection

Wolverine, a division of Wolverine World Wide, Inc. (NYSE:WWW), announced Wednesday it is strengthening its foothold in the lifestyle market through an expanded partnership with award-winning country singer Jordan Davis.

Amgen Rocatinlimab's Data Shows Potential As Long-Term Therapy For Atopic Dermatitis

Amgen Inc. (NASDAQ:AMGN) and Kyowa Kirin released preliminary topline results from the ASCEND study evaluating rocatinlimab in adults and adolescents with moderate to severe atopic dermatitis (AD) on Tuesday.

inkl

Read news from The Economist, FT, and more,
with one subscription

Designer Brands, Oracle And 3 Stocks To Watch Heading Into Tuesday

Designer Brands, Oracle And 3 Stocks To Watch Heading Into Tuesday

With U.S. stock futures trading higher this morning on Tuesday, some of the stocks that may grab investor focus today are as follows:

Shoe Carnival Lifts Profit Outlook As CEO Praises Rebanner Momentum, Stock Soars

Shoe Carnival Lifts Profit Outlook As CEO Praises Rebanner Momentum, Stock Soars

Shoe Carnival, Inc. (NASDAQ:SCVL) shares surged Thursday after the company reported its second-quarter results.

Strong Aerospace Performance Fuels Parker Hannifin To Record Profit

Strong Aerospace Performance Fuels Parker Hannifin To Record Profit

Parker Hannifin Corp. (NYSE:PH) stock is trading higher on Thursday after it reported fiscal fourth-quarter 2025 sales of record $5.24 billion, exceeding analyst expectations of $5.10 billion.

Amgen Stock Sinks As Market Eyes MariTide's Next Move

Amgen Stock Sinks As Market Eyes MariTide's Next Move

Amgen Inc. (NASDAQ:AMGN) shares are trading lower on Wednesday, despite the company reporting second-quarter results that surpassed analyst expectations after markets closed on Tuesday.

Cencora Says Famed GLP-1 Class Products Drive Growth, Boosts Profit Outlook

Cencora Says Famed GLP-1 Class Products Drive Growth, Boosts Profit Outlook

Cencora, Inc. (NYSE:COR) on Wednesday reported third-quarter 2025 sales increased 8.7% to $80.66 billion, beating the consensus of $80.354 billion.

Zoetis Lifts Outlook As Companion Animal Portfolio Offsets Librela Decline

Zoetis Lifts Outlook As Companion Animal Portfolio Offsets Librela Decline

Animal health firm Zoetis Inc. (NYSE:ZTS) on Tuesday reported a second-quarter 2025 adjusted earnings per share of $1.76, up from $1.56 a year ago, beating the consensus of $1.61.

LyondellBasell Defers Projects, Optimizes Portfolio To Weather Extended Cyclical Downturn

LyondellBasell Defers Projects, Optimizes Portfolio To Weather Extended Cyclical Downturn

LyondellBasell Industries N.V. (NYSE:LYB) on Friday reported mixed second-quarter 2025 financial results. Its adjusted earnings missed Wall Street estimates despite revenue topping expectations.

Get all your
news in one place.

100’s of premium titles.
One news app.

Rogers Communications Lifts Outlook After Toronto Sports Deal

Canada’s Rogers Communications, Inc. (NYSE:RCI) shares edged down Wednesday, even as the company delivered an earnings beat in its second-quarter report and raised its full-year service revenue guidance.

Bank Of New York Mellon's Strong Q2 Profit Drives Higher 2025 Guidance

Bank of New York Mellon Corp. (NYSE:BK) on Tuesday reported better-than-expected second-quarter 2025 results, topping both revenue and earnings estimates.

People

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

European Medicines Agency

Bank of New York Mellon

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

313,793 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play